University of Kentucky Alzheimer's Disease Core Center - Biomarker Core

摘要 肯塔基州大学阿尔茨海默病中心（UK-ADC）成立于1985年， 生物标志物倡议的出现，其规模和范围继续增长。我们建议发展一个 生物标志物核心，以丰富UK-ADC，并提供一个基础设施，使我们能够作出重大贡献 死前生物标记的发现UK-ADC专注于从正常到早期的过渡 认知老化导致认知功能障碍的发展。在AD领域的重点转移到早期， 疾病的临床阶段是我们中心的理想定位，该中心专注于认知正常的受试者 以及早期检测和跟踪过去30年来与退行性疾病状态相关的变化。 因此，我们的中心已经收集了700多个血浆样本，100个CSF样本和250个MRI电池， 认知完整的个体。此外，我们有超过350个血浆样本，150个CSF样本和300个MRI样本。 轻度认知障碍患者的电池。在建立生物标志物核心的过程中，我们将建立一个 基础设施，使我们能够分析，分发和跟踪这些有价值的当前和未来的生物标志物 样品基础设施还将为我们提供支持校内，校外和国家的手段 生物标志物计划，如NACC、ADGC/NCRAD、ADNI、ADCS/ATRI和其他NIH/NIA计划。我们将 还建立了一个试验就绪，生物标志物特征，受试者队列，促进入组校内和 校外临床转化研究，以消除招募和筛选失败的瓶颈。最后，我们的中心 一直处于AD模拟物研究的最前沿，包括海马硬化症（HS-Aging），原发性年龄- 相关的tau蛋白病（PART），脑年龄相关的TDP-43和硬化（CARTS），以及血管对 认知障碍和痴呆（VCID）。因此，添加生物标志物核心将使我们能够继续 为这些领域做出贡献，并迅速增长对这些领域生物标志物开发的兴趣。总的来说， 对我们新的生物标志物核心的大力支持将使我们能够增加所需的基础设施， NIH/NIA倡议和我们的研究人员在21世纪及以后的需求。

ABSTRACT The University of Kentucky Alzheimer's Disease Center (UK-ADC) was founded in 1985, prior to the advent of biomarker initiatives that continue to grow in size and scope. We propose the development of a Biomarker Core to enrich the UK-ADC and provide an infrastructure that will allow us to contribute significantly to the discovery of antemortem biomarkers. The UK-ADC has focused on the early transitions from normal cognitive aging to the development of cognitive impairment. The shift of focus in the AD field to earlier, pre- clinical stages of disease ideally positions our center, which has had a focus on subjects with normal cognition and early detection and tracking of changes associated with degenerative disease states for the last 30 years. As a result, our center has collected over 700 plasma samples, 100 CSF samples, and 250 MRI batteries from cognitively intact individuals. Further, we have over 350 plasma samples, 150 CSF samples and 300 MRI batteries from individuals with mild cognitive impairment. In establishing a biomarker core, we will build an infrastructure that allows us to analyze, distribute and track these valuable current and future biomarker samples. The infrastructure will also provide the means for us to support intramural, extramural, and national biomarker initiatives such as NACC, ADGC/NCRAD, ADNI, ADCS/ATRI and other NIH/NIA initiatives. We will also establish a trial-ready, biomarker-characterized, subject cohort, facilitating enrollment into intramural and extramural clinical translational studies to eliminate recruitment and screen fail bottlenecks. Finally, our center has been at the forefront of research on AD-mimics including hippocampal sclerosis (HS-Aging), primary age- related tauopathies (PART), cerebral age-related TDP-43 and sclerosis (CARTS), and vascular contributions to cognitive impairment and dementia (VCID). As such, the addition of a biomarker core will allow us to continue to contribute to these fields and the rapidly growing interest in biomarker development in these areas. Overall, the bolus of support for our new biomarker core will allow us the increased infrastructure needed to support NIH/NIA initiatives and our researchers needs in the 21st century and beyond.